{"prompt": "['Novartis', 'Confidential', 'Page 61', 'Clinical Trial Protocol (Version 00)', 'Protocol No. CQAW039A2317', 'Liver laboratory triggers, which will require repeated assessments of the abnormal', 'laboratory parameter', 'Liver events, which will require close observation, follow-up monitoring and completion', 'of the standard base liver CRF pages', 'Please refer to Table 14-1 in Appendix 2 for complete definitions of liver laboratory triggers', 'and liver events.', 'Every liver laboratory trigger or liver event as defined in Table 14-1 of Appendix 2 should be', 'followed up by the investigator or designated personal at the trial site as summarized below.', 'Detailed information is outlined in Table 14-2 in Appendix 2.', 'For the liver laboratory trigger:', 'Repeating the liver function test (LFT) within the next week to confirm elevation.', 'These LFT repeats must be performed using the central laboratory if possible. If this is not', 'possible, then the repeats can be performed at a local laboratory to monitor the safety of the', 'patient. Repeats laboratory must then be performed at central laboratory as soon as possible. If', 'a liver event is subsequently reported, any local LFTs previously conducted that are', 'associated with this event must be reported on the Liver CRF pages.', 'Repeat laboratory tests must be entered on the appropriate unscheduled local laboratory CRF', 'page.', 'If the elevation is confirmed, close observation of the patient will be initiated, including', 'consideration of treatment interruption if deemed appropriate.', 'For the liver events:', 'Repeating the LFT to confirm elevation as appropriate', 'Discontinuation of the investigational drug if appropriate', 'Hospitalization of the patient if appropriate', 'A causality assessment of the liver event via exclusion of alternative causes (e.g., disease,', 'co-medications)', 'An investigation of the liver event which needs to be followed until resolution.', 'These investigations can include serology tests, imaging and pathology assessments,', \"hepatologist's consultancy, based on investigator's discretion. All follow-up information, and\", 'the procedures performed must be recorded on appropriate CRF pages, including the liver', 'event overview CRF pages.', '7.4', 'Renal safety monitoring', 'The following two categories of abnormal renal laboratory values have to be considered', 'during the course of the study:', 'Serum event:', 'Confirmed (after >24 hours) increase in serum creatinine (sCr) of >25% compared to', 'baseline during normal hydration status.', 'Urine event', 'Albumin-creatinine ratio (ACR) 1g/g or >100 mg/mmol.']['Novartis', 'Confidential', 'Page 62', 'Clinical Trial Protocol (Version 00)', 'Protocol No. CQAW039A2317', 'Protein-creatinine ratio (PCR ) 1g/g or >100 mg/mmol.', 'Every renal laboratory trigger or renal event as defined in Table 15-1 should be followed up', 'by the investigator or designated personnel at the trial site as summarized in Appendix 3.', '7.5', 'Reporting of study treatment errors including misuse/abuse', 'Medication errors are unintentional errors in the prescribing, dispensing, administration or', 'monitoring of a medicine while under the control of a healthcare professional, patient or', 'consumer (European Medicine Agency (EMA) definition).', 'Misuse refers to situations where the medicinal product is intentionally and inappropriately', 'used not in accordance with the protocol.', 'Abuse corresponds to the persistent or sporadic, intentional excessive use of a medicinal', 'product, which is accompanied by harmful physical or psychological effects.', 'Study treatment errors and uses outside of what is foreseen in the protocol will be collected in', 'the DAR (dosage administration record) eCRF irrespective of whether or not associated with', 'an AE/SAE and reported to Safety only if associated with an SAE. Misuse or abuse will be', 'collected and reported in the safety database irrespective of it being associated with an', 'AE/SAE.', 'Table 7-1', 'Guidance for capturing the study treatment errors including', 'misuse/abuse', 'Treatment error', 'Document in Dose', 'Document in AE', 'Complete SAE form', 'type', 'Administration (DAR)', 'eCRF', 'eCRF (Yes/No)', 'Unintentional study', 'Yes', 'Only if associated with', 'Only if associated with an', 'treatment error', 'an AE', 'SAE', 'Misuse/Abuse', 'Yes', 'Yes,', 'Yes, even if not associated', 'with a SAE', 'Abbreviation: eCRF (electronic case report form), AE (adverse event), SAE (serious adverse event).', '7.6', 'Pregnancy reporting', 'To ensure patient safety, each pregnancy occurring after signing the informed consent must be', 'reported to Novartis within 24 hours of learning of its occurrence. The pregnancy should be', 'followed up to the birth of the newborn to determine outcome, including spontaneous or', 'voluntary termination, details of the birth, and the presence or absence of any birth defects,', 'congenital abnormalities, or maternal and/or newborn complications.', 'Pregnancy must be recorded on the Pharmacovigilance Pregnancy Form and reported by the', 'investigator to the local Novartis Drug Safety and Epidemiology Department. Pregnancy', 'follow-up should be recorded on the same form and should include an assessment of the', 'possible relationship to the study treatment.', 'Any SAE experienced during the pregnancy and unrelated to the pregnancy must be reported', 'on a SAE form.']\n\n###\n\n", "completion": "END"}